Truist notes that Argenx (ARGX) announced the discontinuation of the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous in adults with moderate to severe thyroid eye disease, which the firm sees leaving more room for Viridian Therapeutics (VRDN) in that area and more market share up for grabs for both veligrotug and VRDN-003 SC in these patients. The firm keeps a Buy rating and $41 price target on Viridian shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics rises 5.0%
- Viridian Therapeutics: Positioned for Growth with Promising Pipeline and Strong Financials
- Viridian Therapeutics initiated with an Outperform at William Blair
- Viridian Therapeutics initiated with a Buy at Truist
- Promising Developments and Market Potential Drive Buy Rating for Viridian Therapeutics